ClinicalTrials.gg
CompletedNCT03301532Updated Jan 17, 2024Results posted

Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1D

A Phase 2 interventional study of Triheptanoin in GLUT1DS1, sponsored by University of Texas Southwestern Medical Center. Completed at 1 site in United States. Open to participants aged 30 Months to 35 Years. Per ClinicalTrials.gov, last updated 2024-01-17.

Sponsored by University of Texas Southwestern Medical Center · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
30 Months to 35 Years
Sex
All
01

Study summary

To explore triheptanoin (C7 oil) compatibility with the ketogenic diet by evaluating EEG, and seizure rate, glycemia and ketosis in proven G1D patients receiving a ketogenic diet.

Read the detailed description

This is a single site, open label proof of principle exploratory trial to investigate the compatibility of C7 oil with the ketogenic diet in subjects diagnosed with G1D. The ketogenic diet will have been previously described by the patient's treating physician independently of this study and for clinical reasons. The ketogenic diet supplies over 50% of calories from fat, subjects, who are already tolerating over this much fat as part of their previously prescribed ketogenic diet, will replace 45% of their daily caloric intake with the triheptanoin for 24 hours, during a 48 hour inpatient stay. Subjects will have a continuous EEG to monitor for any potential C7 related changes in seizure before, during, and after triheptanoin oil ingestion.

02

Conditions studied

  • GLUT1DS1

Keywords

  • G1D, glucose, transporter
03

In context

Lead sponsor

University of Texas Southwestern Medical Center is the lead sponsor of 1,012 studies on the registry; 200 are open to participants now.

Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Months to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of glucose transporter type 1 deficiency (G1D), confirmed by clinical genotyping at a CLIA-certified laboratory.
  • Stable on ketogenic diet at 2.5:1 to 4:1 ratio (i.e., no changes in ratio will have taken place for 2 months). The initiation of a ketogenic diet is previous to - and thus is not part of this study.
  • Males and females 30 months to 35 years and 11 months old inclusive.

Exclusion criteria

Exclusion Criteria:

  • Subjects with evidence of independent, unrelated metabolic and/or genetic disease.
  • Subjects with a chronic gastrointestinal disorder, such as irritable bowel syndrome, crohn's disease, or colitis that could increase the subject's risk of developing diarrhea or stomach pain.
  • Subjects with a (body mass index) greater than or equal to 30.
  • Subjects currently not on ketogenic diet.
  • Women who are pregnant or breast feeding may not participate. Women who plan to become pregnant during the course of the study, or who are unwilling to use to prevent pregnancy (including abstinence) may not participate. Females age 10 and over will be asked to provide a urine sample for a pregnancy test via dipstick. Subjects will be asked to agree to abstinence or another form of birth control for the duration of the study.
  • Allergy/sensitivity to C7
  • Previous use of triheptanoin less than 1 month prior to study initiation.
  • Treatment with medium chain triglycerides in the last 24 hours.
  • Subjects exhibiting signs of dementia, or diagnosed with any degenerative brain disorder (such as Alzheimer's disease) that would confound assessment of cognitive changes, in the opinion of the investigator.
  • Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
  • Inability or unwillingness of subject or legal guardian/representative to give written , or assent for children age 10-17,
  • Addition of a new antiseizure drug in the previous 3 months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Patients on a ketogenic diet

    This is a one arm study were patients will be receiving an oil called triheptanoin. Patients will be consuming triheptanoin 4 times over the course of one day. The triheptanoin oil will take up 45% of their daily calories on the day the day they are taking the oil.

    Drug: Triheptanoin

Interventions

  • Dietary supplementation with triheptanoin

    Also known as: C7 oil

06

What researchers measure

Primary outcomes

  1. Change in Ketosis (Beta-hydroxybutyrate Levels)

    Change in Ketosis as measured by changes in blood beta-hydroxybutyric acid levels.

    Time frame: Day 1, Day 4

Secondary outcomes

  1. Fraction of Subjects (of a Total of 10 Studied) Who Exhibit a Change in Observable Seizure Rate

    The percent change in observable seizure rate is measured as the change in observable seizure numbers from baseline to Day 4. Seizure rate is defined as count of seizures per patient per day.

    Time frame: Baseline (Day 1) - Day 4

  2. Change in Glycemia

    Change in Glycemia is measured as changes in blood glucose levels.

    Time frame: Day 1 - Day 4

07

Results

Posted Jan 17, 2024

Participant flow

Participant flow — Overall Study
MilestoneExperimental: Triheptanoin (C7)
Started10
Completed10
Not completed0

Outcome measures

PrimaryChange in Ketosis (Beta-hydroxybutyrate Levels)

Change in Ketosis as measured by changes in blood beta-hydroxybutyric acid levels.

Time frame:
Day 1, Day 4
Reported as:
Mean · mM
Change in Ketosis (Beta-hydroxybutyrate Levels)
mMKetosis
Change in Ketosis (Beta-hydroxybutyrate Levels)3.82 ± 1.9
SecondaryFraction of Subjects (of a Total of 10 Studied) Who Exhibit a Change in Observable Seizure Rate

The percent change in observable seizure rate is measured as the change in observable seizure numbers from baseline to Day 4. Seizure rate is defined as count of seizures per patient per day.

Time frame:
Baseline (Day 1) - Day 4
Reported as:
Count of participants · Participants
Fraction of Subjects (of a Total of 10 Studied) Who Exhibit a Change in Observable Seizure Rate
ParticipantsFraction of Subjects With a Change in Seizure Rate
Fraction of Subjects (of a Total of 10 Studied) Who Exhibit a Change in Observable Seizure Rate3
SecondaryChange in Glycemia

Change in Glycemia is measured as changes in blood glucose levels.

Time frame:
Day 1 - Day 4
Reported as:
Mean · mg/dl
Change in Glycemia
mg/dlGlycemia
Change in Glycemia81.2 ± 13.6

Adverse events

Collected over Days 1 - 4. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ketosis0/10 (0%)0/10 (0%)2/10 (20%)
Most frequent other events
Most frequent other events
EventKetosis
SeizuresNervous system disorders2/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Triheptanoin (C7 Oil, Liquid)
<=18 years9
Between 18 and 65 years1
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Triheptanoin (C7 Oil, Liquid)
Female6
Male4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Triheptanoin (C7 Oil, Liquid)
Hispanic or Latino1
Not Hispanic or Latino9
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Triheptanoin (C7 Oil, Liquid)
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White9
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Triheptanoin (C7 Oil, Liquid)
United States9
Argentina1
08

Study locations

1 site
  • UTexasSouthwestern
    Dallas, Texas 75390, United States
09

References and documents

Publications

  • Avila A, Malaga I, Sirsi D, Kayani S, Primeaux S, Kathote GA, Jakkamsetti V, Kallem RR, Putnam WC, Park JY, Shinnar S, Pascual JM. Combination of triheptanoin with the ketogenic diet in Glucose transporter type 1 deficiency (G1D). Sci Rep. 2023 Jun 2;13(1):8951. doi: 10.1038/s41598-023-36001-x. PubMed 37268656 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in Jun 2021, 36 months.

Results were first posted in Jan 2024, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2017
First posted
Oct 4, 2017
StartActual
Jun 5, 2018
Primary completionActual
Jun 18, 2021
CompletionActual
Jul 31, 2022
Results first posted
Jan 17, 2024
Last update
Jan 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03301532
Responsible party
Juan Pascual (Professor of Medicine, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Oct 4, 2017
Start date
Jun 5, 2018
Primary completion
Jun 18, 2021
Completion
Jul 31, 2022
Results posted
Jan 17, 2024
Last update
Jan 17, 2024

Study contacts

Juan Pascual, M.D.
principal investigator · Study Principal Investigator

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triheptanoin

Start the discussion